Invicro becomes the seventh industry partner to join Dementias Platform UK, contributing expertise in brain imaging to further DPUK’s aim to accelerate treatments for dementia.
We are delighted to announce that Invicro, a leading provider of imaging services and software for research and drug development, is now an industry partner of Dementias Platform UK. Invicro joins the consortium of 16 other academic and industry partners who, together, are developing the infrastructure which supports and accelerates a new generation of clinical trials for dementia treatments.
Brain imaging expertise
Formerly known as Imanova, Invicro is uniquely placed to contribute to the work of DPUK, through their place as world experts in brain imaging. Being able to look in detail into the workings of the brain is a crucial element to scientists’ growing understanding of the complex mechanisms which lead to dementia. Scientists across the DPUK network are already benefitting from Invicro’s scientific and technical expertise in state-of-the-art brain imaging.
Invicro constitutes a key part of the DPUK imaging network and has helped to establish the new generation of PET-MR scanners that has been supported by DPUK investment. As one of the seven networked imaging sites, Invicro will be instrumental in multicentre studies, such as the MRC-funded Deep and Frequent Phenotyping study, due to get started early this year.
Invicro, in collaboration with DPUK, is also leading the MINDMAPS programme to establish novel biomarkers of mitochondrial dysfunction and synaptic loss for application to neurodegeneration.
“We are delighted to welcome Invicro as a formal partner of Dementias Platform UK. Invicro is a world leader in the provision of brain imaging services and we look forward to facilitating a new generation of much larger, deeper studies into dementia” John Gallacher, Director, DPUK.
Why Invicro decided to join DPUK
“Invicro is committed to applying imaging to disease understanding and drug development in a range of neurodegenerative diseases. DPUK provides a rich network of disease experts, imaging researchers and commercial organisations who share in the common goal of finding therapies for dementia. DPUK is an important initiative that brings together the best of academia and industry to target dementia and we are excited to be part of it.” Prof Roger Gunn, Executive Vice President – Quantitative Data Sciences, Invicro.
As partners, representatives of Invicro now sit on the Company Partner Forum – a group which advises the work of the platform to ensure it is meeting the needs of industry and making the most of what they have to offer.
Invicro joins a consortium of industry and academic partners at DPUK. By bringing the worlds of university and industry research together in a radical and novel way, DPUK is able to promote cross-fertilisation of ideas, streamline the process from ideas to new treatments, and help researchers to work together on the challenges and opportunities in dementia research.
Based in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Invicro’s multi-disciplinary team provides a full range of image informatics, engineering and operational services. Originally focused on imaging in discovery phase, in 2016 Invicro expanded its offering in clinical phase research with the acquisition of Molecular Neuroimaging, LLC, followed by the acquisition of Imanova and CORE Clinical in 2017. Now through preclinical and clinical divisions, Invicro develops and leverages the latest approaches in imaging quantitative biomarkers. The successful integration of the discovery and clinical teams onto Invicro’s industry-leading software informatics platforms, VivoQuant®® and iPACS®, has inspired a strong and growing presence in the market. For more information, visit www.invicro.com
Dementias Platform UK is a public-private partnership funded by the Medical Research Council. DPUK’s partners – ten universities and seven pharmaceutical companies – have joined forces with the aim of accelerating research towards effective treatment for dementia by improving access to data.
By bringing together records from over 40 different cohort studies – including brain scans, genetics and clinical records – DPUK is creating the world’s richest source of people data for use in research and drug development for dementia. This free-to-access resource of cohort data is available for use by any bona fide researcher who is interested in investigating dementia, whether based within a university or industry context.
DPUK facilitates safe and secure access to this data through its Data Portal, enabling research and analyses at a scale that has not previously been possible for studies into dementia.
DPUK wishes to promote scientific research using cohort study data. It has an active programme of experimental medicine and funds research using cohort data.